SMAD3

Mothers against decapentaplegic homolog 3 · P84022 · SMAD3 on Sugi Atlas →

14,397 patent compounds predicted against SMAD3, 9,337 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL172849	0.49	9/20
SCHEMBL1018988	0.50	6/20
Pochonin D (SCHEMBL669590)	0.42	4/20
Cercosporin (SCHEMBL498747)	0.33	3/20
Aurintricarboxylic Acid (SCHEMBL98495)	0.64	2/20
Aurintricarboxylic Acid (SCHEMBL515038)	0.63	2/20
Aurintricarboxylic Acid (SCHEMBL774684)	0.62	2/20
SCHEMBL134733	0.61	2/20
9,10-Phenanthrenequinone (SCHEMBL43050)	0.59	2/20
SCHEMBL214054	0.59	2/20
SCHEMBL273427	0.59	2/20
SCHEMBL334144	0.57	2/20
SCHEMBL745377	0.57	2/20
SCHEMBL486832	0.57	2/20
SCHEMBL79627	0.56	2/20
SCHEMBL340741	0.56	2/20
SCHEMBL498536	0.55	2/20
SCHEMBL161170	0.54	2/20
SCHEMBL37698	0.53	2/20
SCHEMBL213292	0.52	2/20

Clinical trials — most relevant to SMAD3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS	PHASE4	UNKNOWN
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma	PHASE3	COMPLETED
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies	PHASE2/PHASE3	NOT_YET_RECRUITING
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis	PHASE2/PHASE3	NOT_YET_RECRUITING
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients	PHASE3	UNKNOWN
Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial	PHASE1/PHASE2	COMPLETED
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor	PHASE1/PHASE2	COMPLETED
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)	PHASE2	COMPLETED
The Use of Adhesion Molecule Loaded Hydrogel With Minimally Invasive Surgical Technique in Treatment of Periodontal Intrabony Defect	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis	PHASE2	COMPLETED
Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis	PHASE2	COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors	PHASE1	COMPLETED
Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers	PHASE1	COMPLETED
Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)	PHASE1	COMPLETED
Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis	nan	UNKNOWN
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension	nan	UNKNOWN
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases	nan	NOT_YET_RECRUITING
Glucose Homeostasis and Shared Genetic Factors in Colorectal Cancer	nan	NOT_YET_RECRUITING
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies	nan	UNKNOWN
Role of Nox2 in CNI-induced Renal Fibrosis	nan	COMPLETED
Muscle Wasting in Cancer (MWIC)	nan	COMPLETED
Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)	nan	UNKNOWN
Prevention and Early Detection Biomarkers of Adenomas and CRC Lesions During CRC Screening	nan	COMPLETED
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.	nan	RECRUITING
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension	nan	COMPLETED
Vitamin D Deficiency and Effect of Its Supplementation on Interstitial Lung Diseases(ILD).	nan	UNKNOWN
Role of Extracellular Matrix in the Development of Airway Remodeling in Asthma	nan	UNKNOWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Biomarker Levels During Indwelling Pleural cAtheter Sample Testing	nan	ENROLLING_BY_INVITATION
Epithelial Mesenchymal Transition and Periodontitis	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SMAD3 binder may also engage these)

Protein	Name	Similarity
P84024	—	1.000	P84024 →
P84025	—	1.000	P84025 →
Q8BUN5	—	1.000	Q8BUN5 →
P97588	—	1.000	P97588 →
Q99717	—	1.000	Q99717 →
Q9R1V3	—	0.999	Q9R1V3 →
Q9I962	—	0.999	Q9I962 →
Q9I8V2	—	0.999	Q9I8V2 →
P84023	—	0.999	P84023 →
Q9I9P9	—	0.999	Q9I9P9 →
Q1JQA2	—	0.999	Q1JQA2 →
Q62432	—	0.998	Q62432 →
Q56I99	—	0.998	Q56I99 →
SMAD2	Mothers against decapentaplegic homolog 2	0.997	landscape →
Q5VKP4	—	0.997	Q5VKP4 →
Q9D992	—	0.996	Q9D992 →
Q15797	—	0.996	Q15797 →
O15198	—	0.996	O15198 →
P97454	—	0.996	P97454 →
P42003	—	0.995	P42003 →
Q03495	—	0.995	Q03495 →
Q9NY30	—	0.995	Q9NY30 →
Q9W7E7	—	0.995	Q9W7E7 →
P22474	—	0.995	P22474 →
P89951	—	0.995	P89951 →
Q1W668	—	0.994	Q1W668 →
Q9QBY1	—	0.994	Q9QBY1 →
Q86199	—	0.994	Q86199 →
O59835	—	0.994	O59835 →
P11824	—	0.994	P11824 →